Vaccine

Prevention and control of hepatitis B in central and eastern Europe and the Newly Independent States, Siofok, Hungary, 6-9 October 1996
pp. 1595-1597(3)
Authors: FitzSimons D.; Van Damme P.

Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506)
pp. 1598-1605(8)
Authors: Ogawa T.; Suda Y.; Kashihara W.; Hayashi T.; Shimoyama T.; Kusumoto S.; Tamura T.

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
pp. 1606-1612(7)
Authors: Simondon F.; Preziosi M.-P.; Yam A.; Kane C.T.; Chabirand L.; Iteman I.; Sanden G.; Mboup S.; Hoffenbach A.; Knudsen K.; Guiso N.; Wassilak S.; Cadoz M.

Immunization of seronegative infants with hepatitis A vaccine (HAVRIX(R); SKB): a comparative study of two dosing schedules
pp. 1613-1617(5)
Authors: Troisi C.L.; Hollinger F.B.; Krause D.S.; Pickering L.K.

An effective intradermal hepatitis B vaccination
pp. 1618-1623(6)
Authors: Yamashiki M.; Kosaka Y.; Nishimura A.

Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-1992: protective efficacy and long-term immunogenicity
pp. 1624-1630(7)
Authors: del Canho R.; Grosheide P.M.; Mazel J.A.; Heijtink R.A.; Hop W.C.J.; Gerards L.J.; de Gast G.C.; Fetter W.P.F.; Zwijneberg J.; Schalm S.W.

Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain
pp. 1631-1640(10)
Authors: Hota-Mitchell S.; Siddiqui A.A.; Dekaban G.A.; Smith J.; Tognon C.; Podesta R.B.

Biophysical and antigenic characterization of gonococcal protein I incorporated into liposomes
pp. 1641-1651(11)
Authors: Parmar M.M.; Blake M.S.; Madden T.D.

Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis
pp. 1652-1660(9)
Authors: Garuz R.; Torrea J.L.; Arnal J.M.; Forcen T.; Trinxet C.; Anton F.; Antonanzas F.

A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen
pp. 1661-1669(9)
Authors: Davis D.; Morein B.; &unknown;9kerblom L.; Lovgren-Bengtsson K.; van Gils M.E.; Bogers W.M.J.M.; Teeuwsen V.J.P.; Heeney J.L.

Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies
pp. 1670-1674(5)
Authors: Kurtenbach K.; Dizij A.; Voet P.; Hauser P.; Simon M.M.

Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients
pp. 1675-1679(5)
Authors: Conne P.; Gauthey L.; Vernet P.; Althaus B.; Que J.U.; Finkel B.; Gluck R.; Cryz S.J.

Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines applied as mixed or injected into separate limbs
pp. 1680-1686(7)
Authors: Usonis V.; Bakasenas V.; Willems P.; Clemens R.

DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin
pp. 1687-1696(10)
Authors: Maecker H.T.; Umetsu D.T.; DeKruyff R.H.; Levy S.

Free radical induced polymerization of synthetic peptides into polymeric immunogens
pp. 1697-1705(9)
Authors: Jackson D.C.; O'Brien-Simpson N.; Ede N.J.; Brown L.E.